$223 Million is the total value of Boxer Capital, LLC's 28 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 33.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARDMQ | Sell | ARADIGM CORP | $6,402,000 | +33.0% | 930,513 | -15.5% | 2.87% | -32.8% |
| TSRO | Sell | TESARO INC | $3,508,000 | -44.4% | 35,000 | -53.3% | 1.57% | -71.9% |
| KURA | Sell | KURA ONCOLOGY INC | $3,333,000 | +94.1% | 533,251 | -15.9% | 1.49% | -1.8% |
| EBIO | Sell | ELEVEN BIOTHERAPEUTICS INC | $2,100,000 | +25.7% | 750,000 | -25.0% | 0.94% | -36.5% |
| ACHC | Exit | ACADIA PHARMACEUTICALS INC | $0 | – | -200,938 | -100.0% | -5.78% | – |
| REGN | Exit | REGENERON PHARMACEUTICALS | $0 | – | -20,000 | -100.0% | -6.19% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Aviva Holdings Ltd. #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MIRATI THERAPEUTICS INC | 32 | Q3 2023 | 55.2% |
| BEIGENE LTD | 31 | Q3 2023 | 15.6% |
| KURA ONCOLOGY INC. | 24 | Q3 2021 | 4.7% |
| ROCKET PHARMACEUTICALS INC | 23 | Q3 2023 | 5.4% |
| DBV TECHNOLOGIES S A | 23 | Q3 2023 | 3.9% |
| MEI PHARMA INC | 21 | Q2 2023 | 1.4% |
| SYNDAX PHARMACEUTICALS INC | 20 | Q3 2021 | 3.1% |
| GOSSAMER BIO INC | 19 | Q3 2023 | 4.7% |
| ODONATE THERAPEUTICS INC | 18 | Q1 2022 | 12.5% |
| ESPERION THERAPEUTICS INC NE | 18 | Q2 2021 | 11.0% |
View Boxer Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| IDEAYA Biosciences, Inc. | February 14, 2023 | 2,202,812 | 4.6% |
| Milestone Pharmaceuticals Inc. | February 14, 2023 | 698,861 | 2.0% |
| SpringWorks Therapeutics, Inc. | September 19, 2022 | 3,421,541 | 5.7% |
| iTeos Therapeutics, Inc. | May 11, 2022 | 2,154,058 | 6.1% |
| Atreca, Inc. | February 14, 2022 | 2,202,333 | 7.2% |
| Biomea Fusion, Inc. | February 14, 2022 | 1,188,405 | 4.1% |
| Cabaletta Bio, Inc. | February 14, 2022 | 540,000 | 1.9% |
| CymaBay Therapeutics, Inc. | February 14, 2022 | ? | ? |
| DBV Technologies S.A. | February 14, 2022 | 1,067,299 | 1.9% |
| Elevation Oncology, Inc. | February 14, 2022 | 872,780 | 3.8% |
View Boxer Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-12 |
| 4 | 2024-02-08 |
| SC 13D/A | 2024-02-08 |
| 4 | 2024-01-25 |
| SC 13D/A | 2024-01-25 |
| SC 13G | 2024-01-18 |
| SC 13D/A | 2023-12-18 |
View Boxer Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.